Breast Cancer
Studies from Western General Hospital Reveal New Findings on Breast Cancer
Published in Women's Health Weekly, October 13th, 2011
2011 OCT 13 -- Fresh data on Breast Cancer are presented in the report "The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study." According to the authors of a study from Edinburgh, United Kingdom, "mTOR plays a key role in tumor cell cycle control, proliferation, and survival. RAD001 (everolimus) is a novel macrolide that inhibits mTOR and thus downstream signaling pathways. 31 post-menopausal women with early breast cancer were given 5 mg RAD001 once daily for 14 days prior to surgery."
"Biopsies were taken at diagnosis and at surgery (post 14 days of treatment) and assessed for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
Cellular origin of a rare form of breast cancer identified - Breast Cancer
Data on Breast Cancer Reported by Researchers at Hospital Vall D'Hebron - Breast Cancer
Data on Breast Cancer Reported by S.K. Leivonen and Co-Researchers - Cesarean Section
Data on Cesarean Section Described by Researchers at Ruhr University - Osteoporosis
Data on Osteoporosis Described by D. Karasik et al - Stress Urinary Incontinence
Data on Stress Urinary Incontinence Discussed by Researchers at Ninewells Hospital and School of Medicine - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
